FNIH

The company is testing a five-protein panel in longitudinal samples to see if it could help with early detection and prediction of progression in Alzheimer's.

NEW YORK (GenomeWeb) – The National Institutes of Health said today it has awarded $6 million to 11 research teams for studies that will use genomic and single-cell-level analyses to identify potential therapeutic and diagnostic targets for rheumatoid arthritis and lupus.

NEW YORK (GenomeWeb News) – The National Institutes of Health said today it plans to spend nearly $230 million in a partnership with 10 pharmaceutical firms and several non-profit groups to jumpstart efforts to find targets for new drugs and diagnostics.

NEW YORK (GenomeWeb News) – The Foundation for the National Institutes of Health on Thursday announced that the I-SPY 2 Trial has graduated the first two drugs from its multidrug standing platform trial.

The National Institutes of Health last month announced two funding opportunities with potential microRNA components, seeking grant proposals in the areas of acute kidney injury and the genomic basis of neurodevelopment and mental disorders.

The diagnostic is being developed using a new peptoid-based technique for detecting disease-specific antibodies that could prove broadly useful as a protein biomarker discovery tool, said a researcher.

A plasma-based biomarker test for Alzheimer's could serve as a useful initial screen for the disease, as well as provide drugmakers with a way of selecting trial subjects that could be considerably less expensive than current methods like CSF analysis and PET scans.

The university will help an international effort to study the genetics involved in malnutrition.

Snippets

Premium

Alzheimer's Disease Neuroimaging Initiative, OncoMethylome Sciences, Merck KGaA, 23andMe, Michael J. Fox Foundation for Parkinson's Research, Parkinson's Institute and Clinical Center, and more …

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.